Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Changes to Novasep Governance

Published: Wednesday, October 03, 2012
Last Updated: Wednesday, October 03, 2012
Bookmark and Share
Roger-Marc Nicoud becomes non-executive chairman of the board.

Novasep has announced the appointment of Roger-Marc Nicoud, founder and CEO, as non-executive chairman of the board, effective on October 1st, 2012.

Patrick Glaser, who has been in charge of the Novasep Synthesis division since May 2010, becomes president and CEO, effective on October 1st, 2012.

Bolstered by its new shareholder structure since the completion of its refinancing, Novasep is now in a position to accelerate the development of its activities in France and internationally and to enter into a new phase of growth and investments.

In this regard, Novasep shareholders and Roger-Marc Nicoud have commonly decided to bring about change in the firm's governance by appointing Patrick Glaser, head of the Novasep Synthesis division, as the new President and CEO, while Roger-Marc Nicoud becomes non-executive chairman of the board.

Roger-Marc Nicoud, founder and non-executive chairman of the board of Novasep, said: "As the founder of Novasep and having managed the firm for over 20 years, I think it is the right time for a change in the company's leadership. In a short period of time, our new shareholders have demonstrated their commitment to support the growth of our business by endorsing significant investment, so that we are in a position to take full advantage of our unique leadership in purification technologies. I have been working with Patrick for more than two years and during that time he has successfully grown our chemical activities. I am happy to see him as my successor. With recent sizeable commercial successes, committed shareholders and talented management, Novasep is in good hands. As non-executive chairman of the board, I will work alongside the other board members to ensure a smooth transition. I will continue to share my scientific expertise at board level, in the interests of our customers, shareholders and employees."

Aviva Shneider, former non-executive chairman of the board of Novasep and representative of the shareholders, declared: "On behalf of the board, I want to thank Roger-Marc for the fantastic achievements of a long tenure as the founder and CEO of Novasep. I am pleased that, as my successor as non-executive chairman of the board, he will continue to contribute his unprecedented experience and scientific skills for the benefit of all Novasep's stakeholders. As the representative to the shareholders, I would also like to take this opportunity to reaffirm our commitment to support the growth and expansion of the company and our excitement about its capabilities and prospects."

Thomas Devedjian, director - executive board member of Fonds Stratégique d'Investissement (FSI), declared: "We would like to thank Roger-Marc Nicoud for his very strong involvement in the recovery of the company through the recent refinancing and different promising projects such as the new anti-cancer molecules production capacities in Le Mans. We are thus very confident in the future development of Novasep."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep Strengthens its Advisory Board
Professors Alois Fürstner and Alois Jungbauer, renowned experts in catalysis and purification processes, will help boost innovation at Novasep
Tuesday, September 29, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep’s €4 M ADC Manufacturing Plant Extension Commissioned
The new Highly Potent API manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
Friday, May 16, 2014
Novasep Appoints CEO Michel Spagnol as Chairman
Novasep presents strategic developments.
Wednesday, March 05, 2014
Novasep Opens Indian Subsidiary
New office will meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Tuesday, December 10, 2013
Novasep’s European Custom Manufacturing Passes FDA Inspection
Two successful FDA inspections assure customers of Novasep’s strict compliance with US pharmaceutical processing standards.
Thursday, October 24, 2013
Novasep Appoints Christian Thiry as Chief Financial Officer
CFO appointment is a key milestone in Novasep’s senior management recruitment program.
Thursday, August 29, 2013
Novasep Appoints President and CEO
Novasep announces the appointment of Michel Spagnol as President and CEO of the company, effective from 25 June 2013.
Thursday, June 27, 2013
Novasep Appoints Fine Chemicals Market Director
Company strengthens its position by appointing Udo Steinhauer.
Thursday, June 06, 2013
Novasep Invests to Build World's Largest Chromatography Plant for the Pharmaceutical Industry
The investment of €30 million allows Novasep to build the largest chromatography plant for the production of a large volume commercial API’s in Mourenx, France.
Wednesday, October 10, 2012
Novasep Announces Three Million Euro Investment
Company to boost its highly potent API manufacturing capabilities in Le Mans, France.
Friday, July 20, 2012
Novasep Strengthens its Management Team with Key Appointments
Appointment of Jean-Claude Romain as corporate quality director and Alain Lamproye as director of Novasep Bioproduction sites in Belgium.
Tuesday, April 24, 2012
Novasep Opens New Shanghai Facilities
New site increases Novasep’s process development and engineering capabilities to supply turnkey purification processes in East Asia.
Thursday, March 29, 2012
Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos